Published in Antimicrob Agents Chemother on February 01, 1989
Genetics of Candida albicans. Microbiol Rev (1990) 3.51
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother (1999) 2.67
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 2.60
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev (2006) 2.39
In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother (2003) 2.03
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother (2005) 1.97
Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother (1997) 1.87
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother (2004) 1.82
In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 1.75
Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother (1992) 1.67
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother (1991) 1.37
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother (1990) 1.24
Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother (1997) 1.24
Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother (1991) 1.02
Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob Agents Chemother (1992) 0.95
In vitro and in vivo activity of a novel antifungal small molecule against Candida infections. PLoS One (2014) 0.84
Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. J Infect Dis (2010) 0.82
Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes. Antimicrob Agents Chemother (1993) 0.82
Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection. J Infect Dis (2011) 0.79
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother (1988) 4.79
Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother (1985) 4.68
Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis (1985) 4.00
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother (1985) 3.05
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother (1985) 1.91
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis (1987) 1.53
Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother (1984) 1.52
In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother (1984) 1.48
Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother (1986) 1.29
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice. J Infect Dis (1974) 1.17
Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother (1987) 1.15
Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother (1987) 1.08
Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. J Antimicrob Chemother (1986) 1.01
A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother (1988) 0.95
Therapeutic efficacy of itraconazole in systemic candidosis in guinea pigs. Chemotherapy (1987) 0.83
Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. Exp Hematol (1985) 0.82
The origin and kinetics of mononuclear phagocytes. J Exp Med (1968) 14.96
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Morphology and peroxidase cytochemistry of mouse promonocytes, monocytes, and macrophages. J Exp Med (1970) 4.26
The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ (1972) 4.25
The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med (1970) 4.09
Origin, Kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med (1979) 3.57
Identification and characterization of the monoblast in mononuclear phagocyte colonies grown in vitro. J Exp Med (1975) 3.53
Nitric oxide: a predictor of morbidity in postoperative patients? Lancet (1994) 3.26
Water-related nosocomial pneumonia caused by Legionella pneumophila serogroups 1 and 10. J Infect Dis (1985) 3.16
The kinetics of promonocytes and monocytes in the bone marrow. J Exp Med (1970) 3.12
Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med (1973) 2.94
Origin and kinetics of monocytes and macrophages. Semin Hematol (1970) 2.92
The formation of immunoglobulins by human tissues in vitro. I. The methods and their specificity. Immunology (1966) 2.83
Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax (1995) 2.54
The immunological development of the human fetus. J Exp Med (1965) 2.44
Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest (1979) 2.42
The formation of immunoglobulins by human tissues in vitro. IV. Circulating lymphocytes in normal and pathological conditions. Immunology (1966) 2.40
The origin, kinetics, and characteristics of the Kupffer cells in the normal steady state. J Exp Med (1978) 2.29
Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes. Infect Immun (1977) 2.23
[Side effects of minocycline in the treatment of acne vulgaris]. Ned Tijdschr Geneeskd (1997) 2.06
The effect of glucocorticosteroids on the proliferation and kinetics of promonocytes and monocytes of the bone marrow. J Exp Med (1973) 2.01
Inability of recombinant interferon-gamma to activate the antibacterial activity of mouse peritoneal macrophages against Listeria monocytogenes and Salmonella typhimurium. J Immunol (1987) 1.92
Cloxacillin and nafcillin: serum binding and its relationship to antibacterial effect in mice. J Infect Dis (1973) 1.90
Characteristics of human mononuclear phagocytes. Blood (1979) 1.88
Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis (1992) 1.86
Quantitative studies on the dispersal of skin bacteria into the air. J Med Microbiol (1976) 1.85
Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet (1984) 1.79
Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli. J Infect Dis (1978) 1.79
Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Infect Immun (1981) 1.74
Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. Immunology (1979) 1.73
High levels of interleukin 10 and tumor necrosis factor alpha in cerebrospinal fluid during the onset of bacterial meningitis. Clin Infect Dis (1995) 1.70
Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J (1967) 1.68
In vitro synthesis of lysozyme by human and mouse tissues and leucocytes. Immunology (1975) 1.64
Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 1.61
In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med (1982) 1.56
Kinetics of intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes. Eur J Immunol (1980) 1.55
Origin and turnover of monocytes and macrophages. Curr Top Pathol (1989) 1.54
The formation of immunoglobulins by human tissues in vitro. 3. Spleen, lymph nodes, bone marrow and thymus. Immunology (1966) 1.53
Antimicrobial proteins of murine macrophages. Infect Immun (1993) 1.50
In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man. Immunology (1975) 1.50
In vitro synthesis of immunoglobulins, secretory component and complement in normal and pathological skin and the adjacent mucous membranes. Clin Exp Immunol (1973) 1.50
Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis (1981) 1.48
CD14 contributes to the adherence of human monocytes to cytokine-stimulated endothelial cells. J Immunol (1991) 1.45
Minocycline in the treatment of rheumatoid arthritis: relationship of serum concentrations to efficacy. J Rheumatol (1995) 1.45
Treatment of suspected sporadic cases of Legionnaires' disease. Lancet (1978) 1.43
Cytokines and the host defense against Listeria monocytogenes and Salmonella typhimurium. Biotherapy (1994) 1.42
Kinetics of antimicrobial action. Rev Infect Dis (1981) 1.41
Macrophage activity and clinical immunology. Origin and kinetics of mononuclear phagocytes. Ann N Y Acad Sci (1976) 1.41
Effect of warfarin on the induction and course of experimental endocarditis. Infect Immun (1976) 1.40
[Bacterial meningitis; pathogenesis and current possibilities of additional therapy]. Ned Tijdschr Geneeskd (1992) 1.40
Monocyte adherence to human vascular endothelium. J Leukoc Biol (1993) 1.38
[Immune response following preventive intracutaneous rabies vaccination]. Ned Tijdschr Geneeskd (1991) 1.38
Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand J Haematol (1965) 1.38
Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol (1999) 1.35
Current view on the mononuclear phagocyte system. Immunobiology (1982) 1.35
Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun (1990) 1.32
Divergent changes in antimicrobial activity after immunologic activation of mouse peritoneal macrophages. J Immunol (1987) 1.31
Infection of human vascular endothelial cells with Staphylococcus aureus induces hyperadhesiveness for human monocytes and granulocytes. J Immunol (1997) 1.31
Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis (1993) 1.29
Dual origin of mouse spleen macrophages. J Exp Med (1984) 1.28
The relation between plasma and tissue concentrations of antibiotics. Description of a method. J Pharmacokinet Biopharm (1987) 1.27
Kinetics of phagocytosis and intracellular killing of Staphylococcus aureus and Escherichia coli by human monocytes. Scand J Immunol (1981) 1.27
Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. Infect Immun (1999) 1.27
Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes. Infect Immun (1994) 1.27
Endogenous tumor necrosis factor alpha is required for enhanced antimicrobial activity against Toxoplasma gondii and Listeria monocytogenes in recombinant gamma interferon-treated mice. Infect Immun (1992) 1.25
Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother (1990) 1.25
Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infection. Eur J Clin Microbiol Infect Dis (1988) 1.25
Culture of mononuclear phagocytes on a teflon surface to prevent adherence. J Exp Med (1978) 1.25
The use of lysostaphin in in vitro assays of phagocyte function: adherence to and penetration into granulocytes. Scand J Immunol (1981) 1.25
Properties of a factor increasing monocytopoiesis (FIM) occurring in serum during the early phase of an inflammatory reaction. Blood (1977) 1.24
The formation of immunoglobulins by human tissues in vitro. II. Quantitative studies. Immunology (1966) 1.23
Suspension cultures of mononuclear phagocytes in the teflon culture bag. Cell Immunol (1979) 1.23
Role of granulocytes in experimental Streptococcus sanguis endocarditis. Infect Immun (1982) 1.22
Proliferative characteristics of monoblasts grown in vitro. J Exp Med (1975) 1.22
Effect of thioglycolate on phagocytic and microbicidal activities of peritoneal macrophages. Infect Immun (1984) 1.22
Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine (2000) 1.22
Quantitative immunocytochemical characterization of mononuclear phagocytes. II. Monocytes and tissue macrophages. Immunology (1987) 1.21
The relative potency of amoxycillin and ampicillin in vitro and in vivo. Scand J Infect Dis (1981) 1.20
Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice. Infection (1978) 1.20
Saturation of the tubular excretion of beta-lactam antibiotics. Br J Clin Pharmacol (1988) 1.20
Role of Yops in inhibition of phagocytosis and killing of opsonized Yersinia enterocolitica by human granulocytes. Infect Immun (1995) 1.19
Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun (1996) 1.19
Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette-Guérin. J Exp Med (1981) 1.19
A quantitative evaluation of pulmonary macrophage kinetics. Cell Tissue Kinet (1983) 1.19
Ultrastructure of mononuclear phagocytes developing in liquid bone marrow cultures. A study on peroxidatic activity. J Exp Med (1979) 1.17
Role of granulocytes and monocytes in experimental Staphylococcus epidermidis endocarditis. Infect Immun (1983) 1.16
The formation in vitro of paraproteins in multiple myeloma and Waldenström's macroglobulinaemia. Br J Haematol (1966) 1.15
IgM-IgG cryoglobulinaemia with IgM paraprotein component. Clin Exp Immunol (1968) 1.15
Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J Antimicrob Chemother (1990) 1.13
Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine (2000) 1.13
Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study. J Infect Dis (1983) 1.13
Method to prove investigation of particles by macrophages with light microscopy. Scand J Immunol (1980) 1.12
Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.11
Humoral regulation of monocytopoiesis during the early phase of an inflammatory reaction caused by particulate substances. Blood (1977) 1.10
Origin and kinetics of Kupffer cells during an acute inflammatory response. Immunology (1979) 1.10
Clinical infections and nonsurgical treatment of parapharyngeal space infections complicating throat infection. Rev Infect Dis (1990) 1.09
Activation of mouse peritoneal macrophages during infection with Salmonella typhimurium does not result in enhanced intracellular killing. J Immunol (1990) 1.09
A serum facted by newborn calf serum. Cell Tissue Kinet (1976) 1.09